Hikma to reduce global footprint

Hikma intends to reduce its geographic footprint from its current presence in around 50 countries worldwide, especially by focusing resources on only the most promising markets in the Middle East and North Africa (MENA) region, under a corporate strategy presented by Siggi Olafsson, who became chief executive officer around nine months ago. Olafsson also wants to treble the group’s return on research and development investment within the next five years.

Hikma intends to reduce its geographic footprint from its current presence in around 50 countries worldwide, especially by focusing resources on only the most promising markets in the Middle East and North Africa (MENA) region, under a corporate strategy presented by Siggi Olafsson, who became chief executive officer around nine months ago. Olafsson also wants to treble the group’s return on research and development investment within the next five years.

Stressing Hikma’s differentiating factor of being “the only global local player” in the MENA region, Olafsson said the firm was...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone - Clone

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Testing-Rising

 
• By 

Testing-Rising xxxx

bhvyuguig

lnkbkb

test 1

test 1

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.